Change the Laminin, Change the Cardiomyocyte: Improve Untreatable Heart Failure

• Published in: International journal of molecular sciences Vol. 21; no. 17; p. 6013
• Main Authors: Hochman-Mendez, Camila, Curty, Ernesto, Taylor, Doris A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.08.2020; MDPI
• Subjects: Animals; Biomimetics; cardiomyocyte; Cardiomyocytes; Cardiovascular Agents - pharmacology; Collagen; Compliance; Congestive heart failure; Connectin; Connectin - genetics; Connectin - metabolism; Ejection fraction; Extracellular matrix; Extracellular Matrix - pathology; Fibroblasts; Gene expression; Heart failure; Heart Failure - metabolism; Heart Failure - pathology; Heart Failure - therapy; heart failure with preserved ejection fraction; Humans; Kinases; Laminin; Medical treatment; Morphology; Myocytes, Cardiac - drug effects; Myocytes, Cardiac - pathology; Opinion; Phosphorylation; Phosphorylation - drug effects; polylaminin; Polymers; Protein Isoforms; Proteins; Rats; Signal transduction; Stiffness; titin; United States > US; Texas; titin; heart failure with preserved ejection fraction; cardiomyocyte; laminin; stiffness; polylaminin; extracellular matrix
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21176013

No effective medical treatment exists for heart failure with preserved ejection fraction (HFpEF), accounting for approximately half of all heart failure cases. The elevated passive myocardial stiffness in HFpEF is attributed to a combination of alterations in the extracellular matrix (ECM) collagen content and modifications in the sarcomeric protein titin. Here, we propose polylaminin, a biomimetic polymer of laminin, as a promising approach for manipulating the titin isoform shift and phosphorylation in cardiomyocytes. Exploring the pleiotropic effects of polylaminin may be a novel strategy for alleviating symptoms in HFpEF's multifactorial pathophysiology.